Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

Study analyzed global patterns and trends in ovarian cancer incidence from 1988 to 2017, highlighting variations by ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...

Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in ...

The complex interactions of the tumor–immune–gut axis can shape responses to immunotherapy in ovarian cancer, emphasizing the ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial ...

"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...

Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis No change in IMNN-001 favorable safety profile including no reports of serious immune-related adverse ...